Interpace Biosciences, Inc.
IDXGD
$6.98
-$0.02-0.29%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.09% | -21.56% | -25.68% | -28.78% | -23.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.09% | -21.56% | -25.68% | -28.78% | -23.33% |
| Cost of Revenue | -12.08% | -24.54% | -29.41% | -24.49% | -6.61% |
| Gross Profit | 7.15% | -19.89% | -23.55% | -31.17% | -32.41% |
| SG&A Expenses | 2.69% | -13.72% | -35.86% | -23.29% | 0.38% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.99% | -18.35% | -32.88% | -23.84% | -2.49% |
| Operating Income | 473.21% | -38.60% | 10.48% | -50.24% | -97.87% |
| Income Before Tax | 161.91% | -36.06% | -17.34% | -43.25% | -121.19% |
| Income Tax Expenses | -- | 1,577.78% | -265,112.50% | -375.00% | -- |
| Earnings from Continuing Operations | 149.91% | -52.62% | 1,119.95% | -42.49% | -121.23% |
| Earnings from Discontinued Operations | -0.93% | -2.80% | -693.75% | -21.95% | -44.59% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 124.69% | -56.22% | 1,104.52% | -45.64% | -126.26% |
| EBIT | 473.21% | -38.60% | 10.48% | -50.24% | -97.87% |
| EBITDA | 185.35% | -35.50% | 11.09% | -47.38% | -94.18% |
| EPS Basic | 103.94% | -91.52% | 1,491.17% | -46.03% | -125.98% |
| Normalized Basic EPS | 669.23% | -87.59% | 19.79% | -43.68% | -100.36% |
| EPS Diluted | 103.94% | -53.65% | 153.90% | -90.46% | -126.16% |
| Normalized Diluted EPS | 669.23% | -36.00% | 116.31% | -90.92% | -100.36% |
| Average Basic Shares Outstanding | 526.29% | 415.52% | 0.48% | 0.73% | 1.07% |
| Average Diluted Shares Outstanding | 526.57% | 0.01% | -44.28% | 526.16% | 0.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |